Sell - Price 8.10 on Feb. 10
by Brean Murray Carret & Co.

Elan reported [4Q08] revenue from [multiple-sclerosis treatment] Tysabri of $152 million, [versus] 3Q08 revenue of $165 million. During [partner] Biogen Idec's recent 4Q08 conference call, management disclosed that a fifth patient [has] developed [a rare brain infection] after 12 months' [Tysabri treatment]. Applying a revenue multiple of 6 times and an earnings multiple of 25 times to our 2013 revenue and EPS estimates of $1.2 billion and 29 cents, respectively, and a discount rate of 25%, we get a $4 target, which we view as generous, given the problems. Market cap: $3.8 billion.

From a recent Mad Money show: "No can do. Too hard. I think its a big no right now."

From a recent Mad Money show: "No can do. Too hard. I think its a big no right now."

How Steve Cohen Wins the Game: Debra Borchardt and Alix Steel investigate SAC Capital. Even though Steve Cohen's biggest bets aren't paying off, an amply diversified portfolio is earning him spectacular profits.

Click here to watch the video.

Plastic Surgery First, Mortgage Second: People are struggling to pay their home and car loans but refuse to sacrifice plastic surgery. The business is booming as people find ways to finance their beauty makeovers.

Click here to watch the video.

Elan (ELN) upgraded to Equalweight from Underweight at Lehman based upon recent sharp sell-off. Price target reduced to $14 from $19.

great future

Alzheimers breakthru

Elan (ELN) and Wyeth (WYE) are two biotechs worth watching, according to Pete Najarian.

others have profited; I sold mine too soon

press release not truthful

no growth

it is dead